Health Care/Hospital

ImmVira completed the first dosing for Phase II of MVR-T3011 (intratumoral injection) in the U.S. and China

  SHENZHEN, China, June 11, 2021 /PRNewswire/ -- ImmVira announced that in the Phase II Clinical Trials of its leading oncolytic virus product, MVR-T3011* as intratumoral administration (MVR-T3011 IT), ImmVira has completed the first dosing in bothChina and the U.S. on May 28 2021 and June 11 20...

2021-06-12 11:16 955

United Imaging Splashes Out at SNMMI 2021 With Clinical and Preclinical Technologies, Total-body AI, and Award-Winning Business Programs

HOUSTON, June 11, 2021 /PRNewswire/ -- United Imaging, a global leader in advanced medical imaging and radiotherapy equipment celebrating its tenth anniversary, announced a number of featured products and is highlighting several distinguished speakers at this year's SNMMI, where it is a Silver S...

2021-06-11 20:10 814

Concord Medical Officially Opens New Specialty Cancer Hospital in Guangzhou

BEIJING, June 11, 2021 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specializing in cancer care, research and prevention by operating a network of medically advanced comprehensive cancer hospitals and standalone ...

2021-06-11 18:11 3275

Suzhou Frontera Therapeutics Starts Manufacturing Facility Construction

SUZHOU, China, June 11, 2021 /PRNewswire/ -- Suzhou Frontera Therapeutics Co., Ltd. ('Frontera') starts manufacturing facility construction in BioBay of Suzhou Industrial Park.Xinyan Li, President of Suzhou Frontera hosted, leaders of SIP and bioBay, representatives of investors and other guests ...

2021-06-11 17:19 819

Yingli Pharma Announces a presentation on the Phase 2 clinical trial of linperlisib, a PI3Kδ selective inhibitor, in relapsed or refractory follicular lymphoma at the European Hematology Association 2021 Congress

SHANGHAI, June 11, 2021 /PRNewswire/ -- Shanghai Yingli Pharmaceuticals Ltd (Yingli Pharma), a clinical stage pharmaceutical company providing new therapies for cancer and metabolic diseases, announced today the topline data from a clinical trial sponsored by the company at the annual meeting of ...

2021-06-11 13:05 998

OliPass Expands Scientific Advisory Board by Inviting Experts in Pain To Bolster Phase 2 Clinical Trial Design and Management

SEOUL, South Korea, June 10, 2021 /PRNewswire/ -- OliPass Corporation, a South Korea based biotech specialized in the development of RNA therapeutics, announced that it is expanding its Scientific Advisory Board ("SAB") for SCN9A antisense pain killer OLP-1002 to include ProfessorPatrick M. Do...

2021-06-10 21:00 650

Happiness Biotech Entered Into Electric Vehicle Distribution Agreement With Geely's Subsidiary

NANPING, China, June 10, 2021 /PRNewswire/ -- Happiness Biotech Group Limited (the "Company" or Nasdaq: HAPP), an innovativeChina-based nutraceutical and dietary supplements producer and e-commerce services provider, announced today that Taochejun (Fujian) Automobile Distribution Co., Ltd. ("Taoc...

2021-06-10 21:00 4290

VinBrain and FIT Jointly Release a White Paper on Utilizing Artificial Intelligence in Tuberculosis Screening

HANOI, Vietnam, June 10, 2021 /PRNewswire/ -- On June 10, 2021, VinBrain (Vingroup) and FIT (a German NGO working in the field of Tuberculosis prevention and control) jointly release a white paper on utilizing artificial intelligence (AI) in Tuberculosis (TB) diagnosis and screening inVietnam. Th...

2021-06-10 17:11 530

Verona Pharma and Nuance Pharma Announce $219 Million Strategic Collaboration to Develop and Commercialize Ensifentrine in Greater China

LONDON and RALEIGH, N.C., and SHANGHAI, June 10, 2021 /PRNewswire/ -- Verona Pharma plc (Nasdaq: VRNA) ("Verona Pharma") and Nuance Pharma Limited ("Nuance Pharma"), today announce that the companies have entered into an agreement granting Nuance Pharma, aShanghai-based specialty pharmaceutical c...

2021-06-10 14:00 588

Peijia Medical Partners with inQB8 for US Incubator and Transcatheter Tricuspid Replacement (TTVR) Product

SUZHOU, China, June 9, 2021 /PRNewswire/ -- Peijia Medical (HKEX:9996, or " Peijia"), a leading player in China for medical technology, announced a partnership withinQB8, a Boston based medical technology incubator, to explore innovative solutions for Structural Heart Disease. This partnership inc...

2021-06-10 10:26 5862

Travecta Therapeutics Appoints Charles S. Ryan as President and Chief Executive Officer

SINGAPORE, June 9, 2021 /PRNewswire/ -- Travecta Therapeutics, Pte Ltd., a preclinical stage biopharmaceutical company pioneering a portfolio of product candidates engineered to cross the blood-brain-barrier, today announced the appointment ofCharles S. Ryan, JD, PhD as President and Chief Execut...

2021-06-09 21:00 778

China Pharma to Launch Highly Purified NMN+PQQ Product

HAIKOU, China, June 9, 2021 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced plans to launch a highly purified NMN+PQQ product following the recent successful completion of a pilot scale ...

2021-06-09 20:00 5812

Summit Healthcare Acquisition Corp. Announces Pricing of $200 Million Initial Public Offering

HONG KONG, June 9, 2021 /PRNewswire/ -- Summit Healthcare Acquisition Corp. (the "Company") today announced the pricing onJune 8, 2021 of its initial public offering of 20,000,000 units at a price of$10.00 per unit. The units will be listed on the Nasdaq Capital Market and trade under the ticker ...

2021-06-09 19:17 6799

Waterdrop Inc. to Report First Quarter 2021 Financial Results on June 17, 2021

BEIJING, June 9, 2021 /PRNewswire/ -- Waterdrop Inc. (NYSE: WDH) ("Waterdrop" or the "Company"), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, today announced that it will report its unaudited financial results for the first quarter end...

2021-06-09 19:15 6917

Study of Paxalisib in Primary CNS Lymphoma at Dana-Farber Cancer Institute Enrols First Patient

SYDNEY, June 7, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that a phase II study of Kazia's investigational new drug, paxalisib, in primary CNS lymphoma has been initiated at Dana-Farber Cancer Ins...

2021-06-07 20:00 5666

USANA Malaysia once again named No. 1 combination dietary supplements brand in the country by leading market research company

USANA Malaysia honored by Euromonitor International for third year in a row KUALA LUMPUR, Malaysia, June 6, 2021 /PRNewswire/ -- To be recognized as the top company in your industry is an honor few ever achieve—one USANA Malaysia has now earned for the third year in a row. USANA was recently nam...

2021-06-07 10:22 6059

Yingli Pharma Announces presentations on the Phase 1 trials of linperlisib, a PI3Kδ selective inhibitor, and YL-13027, an oral TGFβR1 inhibitor, at the American Society for Clinical Oncology 2021 Annual Meeting

Clinical trial data will be updated in three presentations on lead drug candidates * Linperlisib, a potent oral PI3Kδ inhibitor, demonstrated robust clinical activity with 70% ORR in relapsed or refractory Peripheral T-cell Lymphoma * Linperlisib is demonstrated to be well-tolerated in a 78 p...

2021-06-04 14:29 1436

AI-based Analysis of Cancer Tissue Predicts Response to Immunotherapy--Findings to Be Presented at ASCO 2021

* Lunit to present four abstracts including one in a 'Poster Discussion Session' * AI-based tissue analysis platform 'Lunit SCOPE' to be launched within the second half of 2021: "We aim to make our AI the new standard for cancer treatment" SEOUL, Korea, June 3, 2021 /PRNewswire/ -- A new find...

2021-06-04 02:14 737

China NMPA Approves MicuRx's Contezolid for Treatment of Drug-Resistant Bacterial Infection

SHANGHAI, June 3, 2021 /PRNewswire/ -- MicuRx Pharmaceutical Co., Ltd. (MicuRx), a leading biopharmaceutical company focused on the discovery, development and commercialization of antibacterial agents against drug-resistant bacterial infection, announced that China National Medical Products Admi...

2021-06-03 22:15 732

iXensor Launches CE-marked Fully Digitized PixoTest COVID-19 Rapid Test with Digital Health Pass to Facilitate Safe Reopening of Economies

* A computer vision empowered rapid antigen test to avoid human errors. * An end-to-end digitized screening solution delivers test-to-report time in around 15 minutes. * The enterprise SaaS solution enables organizations to reopen with confidence. TAIPEI, June 3, 2021 /PRNewswire/ -- iXens...

2021-06-03 17:00 1058
12345 ... 589